A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
Xenon Pharmaceuticals Inc.
450 participants
Dec 20, 2024
INTERVENTIONAL
Conditions
Summary
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Locations(46)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06775379